Advertisement
Advertisement
U.S. markets open in 4 hours 12 minutes
Advertisement
Advertisement
Advertisement
Advertisement

AstraZeneca PLC (AZN.L)

LSE - LSE Delayed Price. Currency in GBp (0.01 GBP)
10,762.00+176.00 (+1.66%)
As of 10:03AM GMT. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close10,586.00
Open10,682.00
Bid10,764.00 x 0
Ask10,766.00 x 0
Day's Range10,662.00 - 10,768.00
52 Week Range8,287.00 - 11,886.00
Volume176,904
Avg. Volume2,140,069
Market Cap166.792B
Beta (5Y Monthly)0.19
PE Ratio (TTM)101.53
EPS (TTM)1.06
Earnings DateFeb 09, 2023
Forward Dividend & Yield2.22 (2.09%)
Ex-Dividend DateAug 11, 2022
1y Target Est125.51
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for AZN.L

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Zacks

      AstraZeneca (AZN) to Report Q4 Earnings: What's in the Cards?

      Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso and Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.

    • MarketWatch

      AstraZeneca says Forxiga approved in EU for heart failure

      AstraZeneca PLC said Tuesday that Forxiga has been approved in the European Union for the treatment of symptomatic chronic heart failure.

    • Reuters

      PRESS DIGEST-British Business - Feb 6

      The following are the top stories on the business pages of British newspapers. The Times - The UK is losing out on investment from AstraZeneca Plc to more competitive countries, Tom Keith-Roach, the head of the company, warned. - A British semiconductor company, IQE Plc could move overseas unless the government sets out its strategy for the sector in the next six months, its chief executive said.

    Advertisement
    Advertisement